Archives
CD147+ Extracellular Vesicles Drive Angiogenesis via PI3K/Ak
2026-05-01
CD147-Positive Small Extracellular Vesicles Orchestrate Angiogenesis in Hepatocellular Carcinoma via PI3K/Akt Signaling
Study Background and Research Question
Hepatocellular carcinoma (HCC) remains the most prevalent primary liver malignancy worldwide and is a leading cause of cancer-related death. Tumor angiogenesis, the process by which new blood vessels are formed, is essential for HCC progression, facilitating both tumor growth and metastatic spread. However, the current diagnostic tools—such as alpha-fetoprotein (AFP) measurement and imaging—often lack sensitivity and specificity, particularly for early-stage or atypical cases. Recent research has shifted focus toward the diagnostic and mechanistic significance of circulating small extracellular vesicles (sEVs), which can shuttle oncogenic proteins and signaling molecules between cells. In this context, Huang et al. set out to identify sEV-associated molecules that not only serve as diagnostic biomarkers, but also actively regulate angiogenesis in HCC (Huang et al., 2023).Key Innovation from the Reference Study
A major innovation of this study is the identification of CD147, a transmembrane glycoprotein, as a significantly enriched component of HCC-derived sEVs. The authors demonstrate that CD147-positive sEVs (CD147+ sEVs) are not merely passive biomarkers, but active participants in the tumor microenvironment, directly promoting angiogenesis in endothelial cells. This dual role—diagnostic and mechanistic—distinguishes CD147+ sEVs from previously characterized vesicular biomarkers in liver cancer (Huang et al., 2023).Methods and Experimental Design Insights
The research team employed a multifaceted approach encompassing clinical sample analysis, in vitro functional assays, and in vivo validation. Key methodological highlights include:- Clinical sEV Profiling: Plasma samples from 155 HCC patients, 59 liver cirrhosis (LC) patients, and 82 healthy donors (HD) were analyzed using nano-flow cytometry (nFCM) to quantify CD147+ sEVs. This enabled robust comparison of sEV populations across disease states.
- Cellular and Molecular Assays: Endothelial cell responses to HCC-derived CD147+ sEVs were interrogated via proliferation, scratch wound healing, transwell migration/invasion, and tube formation assays, providing quantitative and qualitative insights into angiogenic activation.
- Mechanistic Analysis: Levels of vascular endothelial growth factor A (VEGFA) and markers of PI3K/Akt pathway activation were measured following sEV treatment. Pharmacological inhibition and RNA interference experiments further dissected pathway dependencies.
- In Vivo Validation: The angiogenic potential of sEVs was confirmed using a Matrigel plug assay in mice, lending translational relevance to the in vitro findings.
Protocol Parameters
- nano-flow cytometry (nFCM) | 155 HCC, 59 LC, 82 HD samples | Diagnostic biomarker quantitation | Enables high-throughput sEV profiling and comparison across cohorts | paper
- Scratch wound healing assay | 24 h endpoint | Endothelial cell migration | Measures sEV-induced pro-migratory effects on HUVECs | paper
- Tube formation assay | 6 h endpoint | Angiogenesis modeling | Quantifies capillary network formation in vitro upon sEV exposure | paper
- PI3K/Akt inhibition (pharmacological) | Not numerically specified | Pathway dependency assessment | Confirms CD147+ sEV action via PI3K/Akt signaling | paper
- MK-2206 dihydrochloride (typical in vitro use) | 1–2 μM | PI3K/Akt pathway inhibition | Selective allosteric Akt1/2/3 inhibition, suitable for apoptosis and pathway assays | workflow_recommendation
Core Findings and Why They Matter
Huang et al. report several pivotal findings:- Diagnostic Elevation: Plasma CD147+ sEVs are significantly elevated in HCC patients compared to both LC patients and healthy controls. This suggests high potential for non-invasive diagnosis (Huang et al., 2023).
- Functional Angiogenesis Driver: HCC cell-derived CD147+ sEVs enhance proliferation, migration, invasion, and tube formation of endothelial cells, demonstrating their active role in promoting angiogenesis (Huang et al., 2023).
- Mechanistic Pathway: These effects are mediated by the upregulation of VEGFA and activation of the PI3K/Akt signaling pathway within recipient endothelial cells. Inhibiting this pathway abrogates the pro-angiogenic effects of CD147+ sEVs (Huang et al., 2023).
- In Vivo Confirmation: The angiogenesis-promoting capacity of these vesicles is recapitulated in the Matrigel plug mouse model, underscoring the translational relevance.
Comparison with Existing Internal Articles
The PI3K/Akt/mTOR axis is a well-established target in oncology and metabolic research. The current findings align with and extend insights discussed in several internal articles:- Dissecting and Directing the PI3K/Akt/mTOR Signaling Axis explores the mechanistic and translational landscape of MK-2206 dihydrochloride, emphasizing its relevance for dissecting pathway dependencies similar to those elucidated by Huang et al. The reference study offers direct evidence of vesicle-mediated upstream activation, which could be further interrogated using selective inhibitors (internal_article).
- MK-2206 Dihydrochloride: Precision Akt Inhibitor for Cancer highlights the utility of MK-2206 dihydrochloride for functional apoptosis and signaling assays in cancer models. The workflow described is directly applicable for validating the PI3K/Akt dependency of angiogenic processes induced by sEVs (internal_article).
Limitations and Transferability
Despite its strengths, the study has several limitations:- Patient Cohort Diversity: The patient samples were drawn from a single center, and while the numbers are robust, multi-center validation would strengthen generalizability.
- Quantitative Thresholds: While CD147+ sEVs show promise as a biomarker, specific cutoff values for clinical diagnosis require further prospective validation.
- Therapeutic Translation: Although pathway inhibition abrogates angiogenesis in vitro, in vivo therapeutic studies targeting CD147+ sEVs or the PI3K/Akt pathway in HCC models are needed to confirm efficacy and safety.
- Cross-domain Considerations: The mechanistic paradigm is highly relevant for other angiogenesis-driven malignancies, but direct evidence in non-HCC contexts remains to be established (Huang et al., 2023).